VRAX vs. NAVB, ACORQ, NMTR, SBFM, SINT, GRI, BDRX, PBLA, BBLG, and NMRD
Should you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include Navidea Biopharmaceuticals (NAVB), Acorda Therapeutics (ACORQ), 9 Meters Biopharma (NMTR), Sunshine Biopharma (SBFM), Sintx Technologies (SINT), GRI Bio (GRI), Biodexa Pharmaceuticals (BDRX), Panbela Therapeutics (PBLA), Bone Biologics (BBLG), and Nemaura Medical (NMRD). These companies are all part of the "medical" sector.
Navidea Biopharmaceuticals (NYSE:NAVB) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, community ranking, earnings and dividends.
Navidea Biopharmaceuticals has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Comparatively, Virax Biolabs Group has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500.
0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Comparatively, 45.1% of Virax Biolabs Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Virax Biolabs Group has lower revenue, but higher earnings than Navidea Biopharmaceuticals.
Navidea Biopharmaceuticals and Virax Biolabs Group both received 0 outperform votes by MarketBeat users.
In the previous week, Virax Biolabs Group had 2 more articles in the media than Navidea Biopharmaceuticals. MarketBeat recorded 2 mentions for Virax Biolabs Group and 0 mentions for Navidea Biopharmaceuticals. Navidea Biopharmaceuticals' average media sentiment score of 1.44 beat Virax Biolabs Group's score of 0.00 indicating that Virax Biolabs Group is being referred to more favorably in the news media.
Summary
Virax Biolabs Group beats Navidea Biopharmaceuticals on 7 of the 9 factors compared between the two stocks.
Get Virax Biolabs Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Virax Biolabs Group Competitors List
Related Companies and Tools
